BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis by Wilhelm Scott M, Carter Christopher, Tang Liya, Wilkie Dean, McNabola Angela, Rong Hong, Chen Charles, Zhang Xiaomei, Vincent Patrick, McHugh Mark, Cao Yichen, Shujath Jaleel, Gawlak Susan, Eveleigh Deepa, Rowley Bruce, Liu Li, Adnane Lila, Lynch Mark, Auclair Daniel, Taylor Ian, Gedrich Rich, Voznesensky Andrei, Riedl Bernd, Post Leonard E, Bollag Gideon, Trail Pamela A in Cancer research (2004).

[PMID: 15466206] PubMed


Discussed In Paper


Rx Annotations

No dosing information annotated.